Trials / Terminated
TerminatedNCT00638378
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a clinical trial of orally administered Ruxolitinib (INCB018424) in patients whose disease has progressed following 1 prior chemotherapy regimen (not including anti-androgens or ketoconazole) for metastatic, androgen-independent prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib | Ruxolitinib 25 mg tablets taken with water twice a day. |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2008-03-19
- Last updated
- 2018-02-12
- Results posted
- 2012-01-20
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00638378. Inclusion in this directory is not an endorsement.